Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial).
Cari StekCharlotte SchutzLisette BlumenthalFriedrich ThienemannJozefien BuyzeChristiana NöstlingerRaffaella RavinettoEdwin WoutersRobert ColebundersGary MaartensRobert John WilkinsonLutgarde LynenGraeme MeintjesPublished in: JMIR research protocols (2016)
No preventive strategies for TB-IRIS currently exist. If results of this trial demonstrate the efficacy and safety of prednisone, this will provide clinicians with an evidence-based preventive strategy in patients at high risk for paradoxical TB-IRIS when initiating ART.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- mycobacterium tuberculosis
- study protocol
- clinical trial
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- emergency department
- oxidative stress
- patient reported outcomes
- palliative care
- hepatitis c virus
- human immunodeficiency virus
- antiretroviral therapy
- case report
- hiv infected
- phase iii
- pulmonary tuberculosis
- electronic health record
- double blind